{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:59Z","timestamp":1791999299034,"version":"4.4.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156585","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:31:38Z","timestamp":1780936298000},"page":"156585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MGMT promoter methylation in glioblastoma: Molecular mechanisms, tumor microenvironment interactions, and therapeutic implications"],"prefix":"10.1016","volume":"286","author":[{"given":"SM Abdus","family":"Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niaz Mahmood","family":"Tanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shiblee Sadik","family":"Sabuj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Jamilur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Sadekuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhag","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshrat","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Saiful Islam","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9353","authenticated-orcid":false,"given":"Md Rashedunnabi","family":"Akanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156585_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.7150\/thno.124409","article-title":"Coupling proteostasis and de novo purine biosynthesis of PSMD14 fuels glioblastoma progression and chemoresistance","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156585_bib2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/brainsci13111536","article-title":"Advances in glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.prp.2026.156585_bib3","article-title":"Survival rate of patients with glioblastoma treated with radiotherapy and temozolomide compared to radiotherapy alone: a comprehensive systematic review and meta-analysis","volume":"6","author":"Billy","year":"2026","journal-title":"Survival"},{"key":"10.1016\/j.prp.2026.156585_bib4","article-title":"Self-attention-based mixture-of-experts framework for non-invasive prediction of MGMT promoter methylation in glioblastoma using multi-modal MRI","author":"Liao","year":"2026","journal-title":"Displays"},{"key":"10.1016\/j.prp.2026.156585_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/ph19010148","article-title":"Current pharmacotherapeutic strategies in diffuse gliomas: focus on glioblastoma, IDH-wildtype, and emerging targeted therapies for IDH-mutant tumors","volume":"19","author":"Dynarowicz","year":"2026","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.prp.2026.156585_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12883-024-03605-3","article-title":"A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM","volume":"24","author":"Gibson","year":"2024","journal-title":"BMC Neurol."},{"key":"10.1016\/j.prp.2026.156585_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fonc.2018.00448","article-title":"Epigenetic targeting of glioblastoma","volume":"8","author":"Romani","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2532187123","article-title":"Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2\u2032-deoxyuridine (EdU)","volume":"123","author":"Kaanoglu","year":"2026","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib9","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2021-0007","article-title":"Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study","volume":"10","author":"Annavarapu","year":"2021","journal-title":"CNS Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/ijms27020763","article-title":"MGMT, NUPR1, NDRG2, and GLI1 gene promoter methylation in glioblastoma tissues and association with clinical characteristics and therapeutic outcomes","volume":"27","author":"Gabr","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib11","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.3390\/ijms232113034","article-title":"The Significance of MGMT promoter methylation status in diffuse glioma","volume":"23","author":"Jovanovi\u0107","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib12","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.3390\/biomedicines12122732","article-title":"Association of IDH1 mutation and MGMT Promoter methylation with clinicopathological parameters in an ethnically diverse population of adults with gliomas in England","volume":"12","author":"Wanis","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156585_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s43046-025-00296-w","article-title":"IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study","volume":"37","author":"Eid","year":"2025","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2026.156585_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116516","article-title":"Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance","volume":"44","author":"Singh","year":"2025","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-025-05242-3","article-title":"Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma","volume":"176","author":"Gonzalez-Aponte","year":"2026","journal-title":"J. Neuro. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib16","article-title":"Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies","volume":"45","author":"Habibi","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.prp.2026.156585_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328375","article-title":"Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression","volume":"15","author":"Kushihara","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-36379-4","article-title":"MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency","author":"Bhardwaj","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: An updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3390\/cancers16112089","article-title":"Understanding the significance of hypoxia-inducible factors (HIFs) in glioblastoma: a systematic review","volume":"16","author":"Begagi\u0107","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156585_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/cancers12040979","article-title":"Hypoxia inducible factors\u2019 signaling in pediatric high-grade gliomas: role, modelization and innovative targeted approaches","volume":"12","author":"Fuchs","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156585_bib22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s10143-024-03077-6","article-title":"Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis","volume":"47","author":"Rangwala","year":"2024","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.prp.2026.156585_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041342","article-title":"DNA methylation and histone modification in low-grade gliomas: current understanding and potential clinical targets","volume":"15","author":"Ozair","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156585_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712786","article-title":"Long non-coding RNAs in diagnosis, treatment, prognosis, and progression of glioma: a state-of-the-art review","volume":"11","author":"Momtazmanesh","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41419-021-04146-0","article-title":"The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma","volume":"12","author":"Ahmadov","year":"2021","journal-title":"Cell. Death & Dis."},{"key":"10.1016\/j.prp.2026.156585_bib27","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156585_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10571-025-01605-6","article-title":"A MGMT enhancer variant is associated with glioma susceptibility and progression","volume":"45","author":"Zhang","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.prp.2026.156585_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121837","article-title":"Changes of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in glioblastoma relapse-a meta-analysis type literature review","volume":"11","author":"Feldheim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156585_bib30","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1111\/cas.15372","article-title":"miR-3184-3p enriched in cerebrospinal fluid exosomes contributes to progression of glioma and promotes M2-like macrophage polarization","volume":"113","author":"Xu","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.prp.2026.156585_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ibneur.2025.01.015","article-title":"Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma","author":"Jin","year":"2025","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3174\/ajnr.A7004","article-title":"MGMT promoter methylation status in initial and recurrent glioblastoma: correlation study with DWI and DSC PWI features","volume":"42","author":"Choi","year":"2021","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.prp.2026.156585_bib33","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/s41598-026-36379-4","article-title":"MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency","volume":"16","author":"Bhardwaj","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12964-024-01523-y","article-title":"Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages","volume":"22","author":"Tankov","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.prp.2026.156585_bib35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41388-019-0996-y","article-title":"Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-\u03baB pathways","volume":"39","author":"Qian","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2026.156585_bib36","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/cancers11121837","article-title":"Changes of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in glioblastoma relapse\u2014a meta-analysis type literature review","volume":"11","author":"Feldheim","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156585_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17707-w","article-title":"Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach","volume":"12","author":"Do","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10082030","article-title":"MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study","volume":"10","author":"Szylberg","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156585_bib39","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/jcm12052061","article-title":"Identification of MGMT downregulation induced by miRNA in glioblastoma and possible effect on temozolomide sensitivity","volume":"12","author":"Cardia","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2026.156585_bib40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156585_bib41","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.18632\/genesandcancer.197","article-title":"HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1","volume":"10","author":"Santos-Barriopedro","year":"2019","journal-title":"Genes. Cancer"},{"key":"10.1016\/j.prp.2026.156585_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep22477","article-title":"Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma","volume":"6","author":"Parker","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119673","article-title":"MGMT in TMZ-based glioma therapy: multifaceted insights and clinical trial perspectives","volume":"1871","author":"Shaw","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.prp.2026.156585_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/neuonc\/noy132","article-title":"MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges","volume":"21","author":"Mansouri","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prp.2026.156585_bib46","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3390\/biomedicines12092078","article-title":"Epigenetic characteristics in primary and recurrent glioblastoma\u2014influence on the clinical course","volume":"12","author":"Quiring","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156585_bib47","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/glioma.glioma_38_18","article-title":"O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity","volume":"1","author":"Barresi","year":"2018","journal-title":"Glioma"},{"key":"10.1016\/j.prp.2026.156585_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082281","article-title":"The spectrum of molecular pathways in gliomas-an up-to-date review","volume":"11","author":"Nafe","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156585_bib49","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/biology13110885","article-title":"IDH mutations in glioma: molecular, cellular, diagnostic, and clinical implications","volume":"13","author":"Choate","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.prp.2026.156585_bib50","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/jcm15031305","article-title":"Association between MGMT promoter methylation and clinical and lifestyle factors in glioblastoma: a single-center study in Korea","volume":"15","author":"Kim","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2026.156585_bib51","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/neuonc\/nou005","article-title":"The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone","volume":"16","author":"Molenaar","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib52","article-title":"Prognostic significance of MGMT promoter methylation status in idh-mutant glioma","author":"Youssef","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10571-025-01605-6","article-title":"A MGMT enhancer variant is associated with glioma susceptibility and progression","volume":"45","author":"Zhang","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.prp.2026.156585_bib54","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002335","article-title":"Genetic and epigenetic landscape of O(6)-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics","volume":"6","author":"Singh","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"10.1016\/j.prp.2026.156585_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115726","article-title":"Modulating MGMT expression through interfering with cell signaling pathways","volume":"215","author":"Bai","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prp.2026.156585_bib56","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug. Resist."},{"key":"10.1016\/j.prp.2026.156585_bib57","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3174\/ajnr.A7004","article-title":"MGMT promoter methylation status in initial and recurrent glioblastoma: correlation study with DWI and DSC PWI features","volume":"42","author":"Choi","year":"2021","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.prp.2026.156585_bib58","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prp.2026.156585_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.prp.2026.156585_bib60","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-associated hypermutation in gliomas","volume":"20","author":"Choi","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib61","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.3390\/ijms26125634","article-title":"Epigenetic alterations in glioblastoma multiforme as novel therapeutic targets: a scoping review","volume":"26","author":"Meleiro","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103449","article-title":"The dual role of DNA repair protein MGMT in cancer prevention and treatment","volume":"123","author":"Bai","year":"2023","journal-title":"DNA Repair."},{"key":"10.1016\/j.prp.2026.156585_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103449","article-title":"The dual role of DNA repair protein MGMT in cancer prevention and treatment","volume":"123","author":"Bai","year":"2023","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.prp.2026.156585_bib64","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/biology14070838","article-title":"Epigenetic drivers of chemoresistance in nucleobase and nucleoside analog therapies","volume":"14","author":"Kaszycki","year":"2025","journal-title":"Biology"},{"key":"10.1016\/j.prp.2026.156585_bib65","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v13i9.6944","article-title":"Novel strategies for improved treatment of o6-methylguanine-DNA methyltransferase promoter-methylated glioma","volume":"13","author":"Vasquez","year":"2025","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.prp.2026.156585_bib66","article-title":"Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroscience.2025.12.046","article-title":"Predictive and prognostic value of a glucose metabolism disorder and immune-related gene signature in glioma","author":"Lin","year":"2026","journal-title":"Neuroscience"},{"key":"10.1016\/j.prp.2026.156585_bib68","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/cancers16223859","article-title":"Immunophenotypic profile of adult glioblastoma IDH-wildtype microenvironment: a cohort study","volume":"16","author":"Asioli","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156585_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.prp.2026.156585_bib70","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.3390\/ijms22073600","article-title":"Exosomes: Small EVs with large immunomodulatory effect in glioblastoma","volume":"22","author":"Benecke","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib71","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11033-026-11526-2","article-title":"Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges","volume":"53","author":"Tatode","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib72","unstructured":"S.K. Chakrabarti, D. Chattopadhyay, The Epigenetic\u2013Metabolic Axis in Gliomas: Mechanisms and Implications, (2026)."},{"key":"10.1016\/j.prp.2026.156585_bib73","first-page":"2022","article-title":"Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib74","article-title":"Tumor microenvironment in glioblastoma: current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.prp.2026.156585_bib75","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1328375","article-title":"Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression","volume":"15","author":"Kushihara","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12672-025-01894-9","article-title":"Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients","volume":"16","author":"Mo","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib77","article-title":"Molecular and clinicopathological characterization of a prognostic immune gene signature associated With MGMT methylation in glioblastoma","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jocn.2020.01.088","article-title":"Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: correlation with promoter methylation status and patients\u2019 progression-free survival with the cut-off value determined by ROC analysis","volume":"73","author":"Pareira","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.prp.2026.156585_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pe\u00f1a-Romero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156585_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27020763","article-title":"MGMT, NUPR1, NDRG2, and GLI1 gene promoter methylation in glioblastoma tissues and association with clinical characteristics and therapeutic outcomes","volume":"27","author":"Gabr","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib81","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12672-025-01894-9","article-title":"Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients","volume":"16","author":"Mo","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib82","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.3390\/cancers15143739","article-title":"The use of targeted cytokines as cancer therapeutics in glioblastoma","volume":"15","author":"Sooreshjani","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156585_bib83","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/noajnl\/vdae204","article-title":"The glioma microenvironment and its impact on antitumor immunity","volume":"7","author":"Hansen","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.prp.2026.156585_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/00368504251345014","article-title":"Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells","volume":"108","author":"Fang","year":"2025","journal-title":"Sci. Prog."},{"key":"10.1016\/j.prp.2026.156585_bib85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41392-022-01093-w","article-title":"STING cg16983159 methylation: a key factor for glioblastoma immunosuppression","volume":"7","author":"Qiu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156585_bib86","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.7150\/thno.128135","article-title":"STING signaling pathway: an oasis in the glioblastoma immune desert","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156585_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123150","article-title":"The roles of extracellular vesicles in gliomas: Challenge or opportunity?","volume":"358","author":"Huang","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2026.156585_bib89","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fcell.2023.1060000","article-title":"Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells","volume":"11","author":"Musatova","year":"2023","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101167","article-title":"Extracellular vesicles in the glioblastoma microenvironment: a diagnostic and therapeutic perspective","volume":"91","author":"Russo","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.prp.2026.156585_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.vesic.2024.100049","article-title":"Role of extracellular vesicle microRNAs and RNA binding proteins on glioblastoma dynamics and therapeutics development","volume":"4","author":"Singh","year":"2024","journal-title":"Extracell. Vesicle"},{"key":"10.1016\/j.prp.2026.156585_bib92","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/brainsci14111058","article-title":"A systematic review of mesenchymal stem cell-derived extracellular vesicles: a potential treatment for glioblastoma","volume":"14","author":"Agosti","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.prp.2026.156585_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.996805","article-title":"Immunomodulatory effects of extracellular vesicles in glioblastoma","volume":"10","author":"Low","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib94","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1423232","article-title":"Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: on the border of kingdoms","volume":"15","author":"Ghazi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1423232","article-title":"Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: on the border of kingdoms","volume":"15","author":"Ghazi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib96","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12951-024-02888-5","article-title":"Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway","volume":"22","author":"Xue","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.prp.2026.156585_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216792","article-title":"Hypoxia effects on glioblastoma progression through YAP\/TAZ pathway regulation","volume":"588","author":"Castillo","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156585_bib98","first-page":"2025","article-title":"Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12935-025-03823-w","article-title":"HIF-1\u03b1 and HIF-2\u03b1: synergistic regulation of glioblastoma malignant progression during hypoxia and apparent chemosensitization in response to hyperbaric oxygen","volume":"25","author":"Wang","year":"2025","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.prp.2026.156585_bib100","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cells12050798","article-title":"Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators","volume":"12","author":"Yfantis","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156585_bib101","doi-asserted-by":"crossref","unstructured":"L. Persano, F. Pistollato, E. Rampazzo, A. Della Puppa, S. Abbadi, C. Frasson, et al., BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1\u03b1 stability and MGMT expression, in: Cell Death Dis, pp. e412. https:\/\/doi.org\/10.1038\/cddis.2012.153.","DOI":"10.1038\/cddis.2012.153"},{"key":"10.1016\/j.prp.2026.156585_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/lifemedi\/lnad048","article-title":"Hypoxia-induced one-carbon metabolic reprogramming in glioma stem-like cells","volume":"2","author":"He","year":"2023","journal-title":"Life Med."},{"key":"10.1016\/j.prp.2026.156585_bib103","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. & Mol. Med."},{"key":"10.1016\/j.prp.2026.156585_bib104","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1021\/acs.biochem.5c00632","article-title":"Hypoxia rewires histone methylation in glioblastoma cells via enzyme reprogramming despite disruption of one-carbon metabolism","volume":"64","author":"Tang","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.prp.2026.156585_bib105","article-title":"Potential targets and treatments affect oxidative stress in gliomas: an overview of molecular mechanisms","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2026.156585_bib106","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/ijms17060984","article-title":"ROS and brain gliomas: an overview of potential and innovative therapeutic strategies","volume":"17","author":"Rinaldi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib107","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.934161","article-title":"Identifying the predictive role of oxidative stress genes in the prognosis of glioma patients","volume":"27","author":"Lu","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.prp.2026.156585_bib108","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/antiox14091121","article-title":"Oxidative stress and antioxidants in glioblastoma: mechanisms of action, therapeutic effects and future directions","volume":"14","author":"Nowacka","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.prp.2026.156585_bib109","doi-asserted-by":"crossref","DOI":"10.1177\/00368504251345014","article-title":"Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells","volume":"108","author":"Fang","year":"2025","journal-title":"Sci. Progress."},{"key":"10.1016\/j.prp.2026.156585_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245777","article-title":"Association of MGMT promoter and enhancer methylation with genetic variants, clinical parameters, and demographic characteristics in glioblastoma","volume":"15","author":"Zappe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156585_bib111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13014-020-01549-9","article-title":"A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma","volume":"15","author":"Straube","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103645","article-title":"Effectiveness of different treatment strategies in elderly patients with glioblastoma: An evidence map of randomized controlled trials","volume":"173","author":"Ma","year":"2022","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.prp.2026.156585_bib113","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41416-023-02317-8","article-title":"Radiogenomics: a key component of precision cancer medicine","volume":"129","author":"Liu","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156585_bib114","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v13i9.6944","article-title":"Novel strategies for improved treatment of o6-methylguanine-DNA methyltransferase promoter-methylated glioma","volume":"13","author":"Vasquez","year":"2025","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.prp.2026.156585_bib115","doi-asserted-by":"crossref","first-page":"18241","DOI":"10.1021\/jacs.3c06483","article-title":"Mechanism of action of KL-50, a candidate imidazotetrazine for the treatment of drug-resistant brain cancers","volume":"146","author":"Huseman","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.prp.2026.156585_bib116","doi-asserted-by":"crossref","first-page":"12609","DOI":"10.1021\/acsami.0c01514","article-title":"Delivery of temozolomide and N3-propargyl analog to brain tumors using an apoferritin nanocage","volume":"12","author":"Bouzinab","year":"2020","journal-title":"ACS Appl. Mater. & Interfaces"},{"key":"10.1016\/j.prp.2026.156585_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041003","article-title":"PARP inhibitors in glioma: a review of therapeutic opportunities","volume":"14","author":"Sim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156585_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118255","article-title":"DNMT1 drives glioma progression and modulates therapy response: a novel therapeutic target","volume":"301","author":"Armoundas","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2026.156585_bib119","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00221-023-06693-8","article-title":"Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway","volume":"241","author":"Zhao","year":"2023","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.prp.2026.156585_bib120","doi-asserted-by":"crossref","unstructured":"R. Yasser, K.K. Arafa, N.K. Sedky, K.R. Sidaros, R.K. Arafa, BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents, in: N. Rezaei (Ed.), Novel Approaches in Cancer Treatment: Tumor Targeted Therapy, Springer Nature Switzerland, Cham, pp. 883-911. https:\/\/doi.org\/10.1007\/978-3-032-00771-1_401.","DOI":"10.1007\/978-3-032-00771-1_401"},{"key":"10.1016\/j.prp.2026.156585_bib121","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202502901R","article-title":"The application of PD-1 inhibitors in immunotherapy for glioblastoma","volume":"40","author":"Dong","year":"2026","journal-title":"Faseb J."},{"key":"10.1016\/j.prp.2026.156585_bib122","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. & Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib123","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2025.1616872","article-title":"New dimensions of PD-1\/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives","volume":"16","author":"Tong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156585_bib124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13578-024-01305-6","article-title":"Research progress and challenges of the PD-1\/PD-L1 axis in gliomas","volume":"14","author":"Jiacheng","year":"2024","journal-title":"Cell. & Biosci."},{"key":"10.1016\/j.prp.2026.156585_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cells14181458","article-title":"Tumor-associated macrophages in glioblastoma: mechanisms of tumor progression and therapeutic strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156585_bib126","first-page":"2021","article-title":"Molecular and clinicopathological characterization of a prognostic immune gene signature associated With MGMT methylation in glioblastoma","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156585_bib127","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21873\/invivo.12239","article-title":"Inhibition of colony-stimulating factor-1 receptor enhances the efficacy of radiotherapy and reduces immune suppression in glioblastoma","volume":"35","author":"Almahariq","year":"2021","journal-title":"Vivo"},{"key":"10.1016\/j.prp.2026.156585_bib128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s40644-024-00817-1","article-title":"Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.prp.2026.156585_bib129","first-page":"2025","article-title":"Radiomics prediction of MGMT promoter methylation in adult diffuse gliomas: a combination of structural MRI, DCE, and DTI","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prp.2026.156585_bib130","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1038\/s41598-025-87803-0","article-title":"Deep learning classification of MGMT status of glioblastomas using multiparametric MRI with a novel domain knowledge augmented mask fusion approach","volume":"15","author":"Koska","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156585_bib131","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1590\/S1807-59322011001000013","article-title":"Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma","volume":"66","author":"Uno","year":"2011","journal-title":"Clin. (Sao Paulo)"},{"key":"10.1016\/j.prp.2026.156585_bib132","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jmoldx.2013.05.011","article-title":"The role of MGMT testing in clinical practice","volume":"15","author":"Cankovic","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.prp.2026.156585_bib133","article-title":"High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas","volume":"2009","author":"Parrella","year":"2009","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.prp.2026.156585_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137148","article-title":"MGMT and whole-genome DNA methylation impacts on diagnosis, prognosis and therapy of glioblastoma multiforme","volume":"23","author":"Della Monica","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156585_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152728","article-title":"High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma","volume":"216","author":"Braczynski","year":"2020","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.prp.2026.156585_bib136","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11060-025-05015-y","article-title":"Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients","volume":"173","author":"Shen","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.prp.2026.156585_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.htct.2026.106322","article-title":"Liquid biopsy for non-invasive assessment of mgmt gene methylation in glioblastoma: a pilot study","volume":"48","author":"Lima","year":"2026","journal-title":"Hematol. Transfus. Cell. Ther."},{"key":"10.1016\/j.prp.2026.156585_bib138","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156585_bib139","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing--the challenges for biomarker-based glioma treatment","volume":"10","author":"Wick","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.prp.2026.156585_bib140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41591-018-0156-x","article-title":"The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space","volume":"24","author":"Klughammer","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2026.156585_bib141","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/neuonc\/nop050","article-title":"O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications","volume":"12","author":"Brandes","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156585_bib142","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:42:45Z","timestamp":1786502565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":142,"alternative-id":["S0344033826002384"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156585","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MGMT promoter methylation in glioblastoma: Molecular mechanisms, tumor microenvironment interactions, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156585"}}